Aminolevulinic acid hydrochloride is under clinical development by SonALASense and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Recurrent Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Aminolevulinic acid hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aminolevulinic acid hydrochloride overview
Aminolevulinic acid hydrochloride is under development for the treatment of recurrent glioblastoma multiforme, primary glioblastoma multiforme, diffuse intrinsic pontine glioma (DIPG), recurrent high-grade glioma, brain metastasis, meningioma, pancreatic cancer, ovarian cancer, gastric cancer, bladder cancer, liver cancer and gall bladder cancer. The therapeutic candidate is administered through intravenous route.
SonALASense overview
SonALASense providing sonodynamic therapy that provides noninvasive and safe treatment for Glioblastoma. It is headquartered in Berkeley, California, the US.
For a complete picture of Aminolevulinic acid hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.